Correction: MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene

Shanbao Cai; Youguang Pu; Fangfang Zhao; Haiyan Wang; Wenjing Cai; Jin Gao; Yinpeng Li

doi:10.18632/oncotarget.20599

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene

PDF | How to cite

Oncotarget. 2017; 8:60723-60723. https://doi.org/10.18632/oncotarget.20599

Metrics: PDF 2571 views | ?

Shanbao Cai^1,6,*, Youguang Pu^1,*, Fangfang Zhao^1,*, Haiyan Wang², Wenjing Cai³, Jin Gao⁴, Yinpeng Li⁵

¹ Cancer Epigenetics Program, Anhui Cancer Hospital, West District of Anhui Provincial Hospital, Hefei 230031, Anhui, China
² Department of Clinical Geriatrics, Anhui Provincial Hospital, Hefei 230031, Anhui, China
³ Indiana University School of Medicine, Indianapolis, IN 46202, USA
⁴ Department of Radiation Oncology, Anhui Cancer Hospital, West District of Anhui Provincial Hospital, Hefei 230031, Anhui, China
⁵ Xinxiang Medical University, Xinxiang 453000, Henan, China
⁶ Department of Orthopedic Surgery, Anhui Cancer Hospital, West District of Anhui Provincial Hospital, Hefei 230031, Anhui, China
^* These authors have contributed equally to this work

Published: September 01, 2017

This article has been corrected: Dr. Shanbao Cai was moved to the first position in the author list. The authors sincerely apologize for this oversight.

Original article: Oncotarget. 2016;7:28420-34. DOI:https://doi.org/10.18632/oncotarget.8546.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20599

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: MiR-34a-5p promotes the multi-drug resistance of osteosarcoma by targeting the CD117 gene